论文部分内容阅读
目的:分析曼月乐联合醋酸亮丙瑞林治疗子宫腺肌症临床疗效。方法:选择我院2014年4月至2017年4月我院所收治的80例子宫腺肌症患者作为研究对象。按照随机数字法分为实验组与常规组。常规组患者仅采用醋酸亮丙瑞林进行治疗,实验组患者在常规组基础上采用曼月乐进行治疗。对比两组患者的治疗效果。结果:治疗后两组患者的FSH、HL、E2三项指标无明显差异,数据不具备统计学意义(P>0.05);实验组患者的痛经症状改善情况指标显著优于常规组患者,数据差异均显著,具备统计学意义(P<0.05)。结论:曼月乐联合醋酸亮丙瑞林治疗子宫腺肌症临床疗效显著,是一种安全、高效的治疗方式,值得临床推广。
Objective: To analyze the clinical efficacy of Mirena combined with leuprolide in the treatment of adenomyosis. Methods: Eighty patients with adenomyosis admitted to our hospital from April 2014 to April 2017 were selected as the study subjects. According to random number method divided into experimental group and conventional group. Patients in the conventional group were treated with leuprolide only, and patients in the experimental group were treated with Mirena on the basis of the conventional group. Compare the treatment effect of two groups of patients. Results: There was no significant difference in FSH, HL and E2 between the two groups after treatment (P> 0.05). The indexes of dysmenorrheal symptom improvement in the experimental group were significantly better than those in the conventional group Significantly, with statistical significance (P <0.05). Conclusion: Mirenale combined with leuprolide acetate in the treatment of adenomyosis clinical efficacy is significant, is a safe and efficient treatment, worthy of clinical promotion.